Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM.F. Mosele, Fabrice André, C. Benedikt Westphalen et al.|Annals of Oncology|2024Cited by 343
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT StudyElizabeth Bancroft, Apollonia T. Helderman-van den Enden, Elizabeth Page et al.|European Urology|2014Cited by 250
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK.N. Chi, Eleni Efstathiou, Eric J. Small et al.|Annals of Oncology|2023Cited by 195
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Alberto Bossi et al.|European Journal of Cancer|2023Cited by 156
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendationsZeid Kuzbari, Chaitanya Bandlamudi, Chey Loveday et al.|Annals of Oncology|2022Cited by 133